

Hypertonic Saline In Traumatic Brain Injury: Current Status

Lt Col Kavita Sandhu MD, Lt Col TVSP Murthy MD, Brig T Prabhakar MD, VSM
Department of Anesthesiology, Army Hospital Research & Referral, Delhi Cantt

Abstract: Traumatic brain injury is among the leading causes of mortality today. Systemic hypotension and intracranial hypertension are major contributors towards morbidity and mortality in these patients. The primary goal of resuscitation is to maintain adequate blood pressure while attenuating the expected rise in intracranial pressure. The type of fluid to be used for this is much debated even today. Mannitol is the most popular agent, but there are limitations to its administration. Interest is now focusing on the utility of other hyperosmolar agents like hypertonic saline, that combat raised intracranial pressure and support intravascular volume. However, no standards exist regarding its indications or optimal administration regimen in the treatment of traumatic brain injury. A review of literature regarding the postulated mechanism of action and current status of its role in traumatic brain injury is discussed.

Keywords: head injury, hypertonic saline, traumatic brain injury, intracranial pressure, resuscitation

Traumatic brain injury is among the leading causes of mortality today. Out of these patients, 60-90% have diffuse cerebral edema, herniation or necrosis¹. This secondary brain injury is attributable to a decrease in cerebral oxygen delivery as a result of hypoxia, systemic hypotension or relative hypoperfusion produced by intracranial hypertension². On the basis of available prospective, randomized controlled studies, it is apparent that while treating a brain-injured patient, hypoxia, systemic hypotension and intracranial hypertension must be avoided^{3,4}. The primary goal of resuscitation is therefore to maintain adequate blood pressure while attenuating the expected rise in ICP.¹ The type of fluid to be used for this resuscitation and its rate of administration are much debated even today.

Hyperosmolar therapy is the cornerstone of treatment for raised ICP. Mannitol is the most popular agent but there are limitations to its administration. Although mannitol can decrease ICP in TBI, prolonged administration may lead to intravascular dehydration, hypotension, prerenal azotemia as well as reduction of cerebral blood flow⁵. For these reasons and because standard therapy and barbiturates do not always control ICP, interest has now been focusing on the utility of other hyperosmolar agents that can not only combat raised intracranial pressure but also support intravascular volume⁶. Weed and Mckibben first reported a reduction in ICP following use of hypertonic saline, in 1919⁷. In models of brain injury, animals resuscitated with HTS exhibit resolution of shock, reduction of intracranial pressure and alleviation of cerebral edema^{8,9}. In human

studies also, similar effects have been reported along with enhanced cardiovascular performance^{10,11}. However, no standards exist regarding the indications or optimal administration regimen for HTS in the treatment of TBI. A review of literature regarding the potential mechanisms of action and the current status of its role in TBI is presented

Mechanisms of Action

The exact mechanism by which HTS acts on the injured brain remains to be fully elucidated. Animal and human studies suggest that HTS possesses osmotic, vasoregulatory, haemodynamic, neurochemical and immunologic properties. TBI is a multifactorial disorder and HTS works on several areas simultaneously. Some of the postulated mechanisms are as follows-

1) Haemodynamic effects:

In TBI, secondary ischaemia often results from hypoperfusion of the injured brain¹². Moreover, neurotrauma itself may alter compensatory mechanisms and increase susceptibility to shock and multiorgan failure¹³. The ability of HTS to improve and maintain mean arterial pressure occurs as a result of plasma volume expansion. In addition there may also be centrally mediated effects on the cardiac output, possibly via changes in circulating hormone levels¹⁴. This improvement in blood pressure does not come at the expense of high infusion volumes and increased ICP as in the case of isotonic resuscitation¹⁵. Thus, cerebral perfusion pressure maybe improved with HTS, leading to better perfusion of the injured brain.

2) Intracranial pressure effects:

The osmotic effect of HTS on the injured brain improves

Address for correspondence: Lieut Col K Sandhu, Department of Anesthesiology, Army Hospital (R & R), Delhi Cantt 110010

perfusion by drawing fluid from the tissue into the intravascular compartment¹⁶. Both animal and human studies have demonstrated this ability of HTS to lower ICP, whether given as a bolus or continuous infusion^{17,18}. Agents like mannitol also dehydrate edematous tissue. However, the blood brain barrier is better able to exclude HTS because of tight gap junctions and its higher polarity, resulting in a reflection coefficient of 1.0 for sodium chloride as compared to 0.9 for mannitol¹⁷. Also, HTS does not possess the osmotic diuretic properties of mannitol and subsequent problems with volume depletion and hypotension maybe avoided.

Osmolytes, a group of organic solutes have an important role to play in the action of HTS. These organic solutes include certain amino acids, polyhydric alcohols and methylxanthines¹⁹. They can be released from or transported into cells in response to changes in extracellular osmolarity²⁰. Animal studies document extrusion of these osmolytes into the extracellular space by several mechanisms including cell depolarization, cell membrane leakage and reversal of sodium dependent cotransporters^{21,22}. An increase in extracellular sodium helps restore cotransporters and normal cell polarity²³. In addition, HTS helps draw fluid from the edematous brain, which contains extruded osmolytes, to the vascular compartment, thereby decreasing ICH²⁴. The cells respond to the increase in extracellular osmolarity by pulling osmolytes intracellularly. This process requires active transport and takes three or more days to achieve²⁵. This explains the results of human trials where tolerance to effects of HTS was seen. A 10-15 mEq/l rise in serum sodium was found to lower ICP for approximately 72 hrs²⁶.

3) Vasoregulatory effects:

Vasomotor dysfunction and resultant cerebral ischaemia is a significant contributor to secondary brain injury²⁷. In addition, endothelial cell edema occurs after trauma. HTS appears to counter this hypoperfusion and vasospasm by increasing the vessel diameter and expanding plasma volume²⁸.

4) Immunomodulatory effect:

HTS has been shown to have immunomodulatory effects in patients with trauma. Inflammation is an important component of the pathophysiology of TBI. Cerebral leukocytes migrate to the injured areas of the brain leading to peroxidase and protease mediated cell death. Also, release of inflammatory mediators like eicosanoids cause vasospasm and interstitial edema²⁹. In animal models, HTS has been found to counteract this chain of events and increase the circulating levels of cortisol and ACTH^{30,31}.

5) Neurochemical effects:

Following TBI, neuronal depolarization occurs accompanied by a concomitant rise in extracellular glutamate. Further, cerebral ischaemia leads to a decrease in ATP, lowering the amount of substrate available to sodium and potassium exchangers. This leads to a decrease in extracellular sodium levels and a reversal of the normal sodium/glutamate cotransporter thereby further raising extracellular glutamate³². HTS acts by decreasing the influence of glutamate after TBI. The raised extracellular sodium interrupts the feedback loop and helps to reestablish the normal direction of sodium/glutamate cotransporter²³.

HTS to control ICP

Animal models demonstrating the efficacy of HTS in reducing ICP are plentiful. Human trials are relatively few and mainly limited to patients who have failed conventional management.

Worthley et al reported two patients with TBI who had ICP elevations refractory to mannitol³³. They successfully treated the ICH with 20 ml of 29.9% HTS. Einhaus et al reported a similar experience in a TBI patient where a single bolus of 7.5% HTS was used³⁴. Suarez et al³⁵ described 8 patients in whom 23.4% HTS was used for ICP control after failure of mannitol therapy. Although only one patient had TBI in this study, a significant decrease in ICP was noted in all the patients and the effect lasted several hours. A significant observation was the absence of a rise in serum sodium despite repeated administrations of 30 ml boluses of this HTS.

Horn et al³⁶ studied the effects of a bolus dose of 7.5% HTS on elevated ICP refractory to both barbiturates and mannitol. A decrease in ICP from a mean of 33 mm Hg to 19 mm Hg was observed after one hr and the effect lasted about three hours. Mean serum sodium levels rose by only 2 mEq/l³⁷.

Simma et al³⁷ were the first to perform a prospective randomized trial to evaluate HTS in pediatric head injuries using either 1.7% HTS or Ringer Lactate as the maintenance fluid therapy for the first 72 hrs after injury. Patients receiving HTS had lower ICP values and required fewer interventions to manage ICP elevations. Less fluid was required to maintain blood pressure in the HTS group, which also displayed improved survival. This study was of particular significance as it was the earliest in which HTS was given over the entire 72 hr period and the results were not modified by the use of isotonic maintenance fluids.

Qureshi et al¹⁶ evaluated the effects of continuous HTS in 8 patients with ICH due to various causes. They administered 3% HTS to raise the serum sodium from 145

to 155 mEq/l. An inverse relationship between serum sodium and ICP was observed in TBI or postoperative edema. The beneficial effect lasted 3 days following which 4 patients required pentobarbital for rebound increase in ICP. The same group retrospectively studied 36 patients of severe TBI who received continuous infusion of 2% or 3% HTS to achieve a serum sodium of 145 to 155 mEq/l.³⁸ These were compared to a control group who did not receive HTS. Once again, more patients in the HTS group required barbiturate coma and had higher hospital mortality. They concluded that continuous infusion might not be the ideal method of administering HTS and recommended bolus administration.

Khanna and coworkers²⁶ tried a continuous infusion of 3% HTS in pediatric cases of severe TBI and intracranial hypertension refractory to other treatment modalities. The target serum sodium was continually increased as needed to control ICP. Mean serum sodium levels of 170 mEq/l were reached. An inverse relationship between serum sodium and ICP was observed. Furthermore, an increase in serum sodium was associated with decreased requirements for other therapies to control ICP. Overall outcome was excellent with no adverse effects.

Peterson et al³⁹ did a retrospective study on the effect of a continuous infusion of 3% hypertonic saline on ICP control in pediatric closed head injuries. They found that the treatment effectively lowered ICP in all except 3 of the 68 patients. No adverse effects were noted. They concluded that administration of hypertonic saline in pediatric head injuries appears to be a promising therapy for control of cerebral edema. They recommended further control trials to determine the optimal duration of treatment before widespread use is advocated.

HTS for prehospital resuscitation in TBI

Head injury often occurs in a setting of polytrauma and maybe accompanied by hemorrhagic shock. Traumatic brain injury by itself can blunt cardiac and vascular compensatory responses to shock, leading to profound hypotension even in the absence of hemorrhage⁴⁰. The injured brain is especially vulnerable to ischemic injury from hypoperfusion following hypotension. Thus the primary goal of acute resuscitation in TBI includes maintaining adequate blood pressure while attenuating the rise in ICP⁴¹.

Vassar et al¹¹ were among the first to evaluate HTS as a prehospital resuscitation fluid. Dextran(4.2%) was added to HTS on the basis of its potential to augment favourable haemodynamic effects of HTS. Twenty trauma patients were randomized to receive either 7.5% HTS-Dextran or Lactated Ringer (250ml each), followed by supplemental

Lactated Ringer as needed, to maintain a SBP of 100mmHg or greater. They observed a significant increase in SBP and overall survival in patients receiving HTS. The same group conducted another prospective randomized trial in 258 trauma patients where they administered 7.5%HTS, 7.5% HTS with 6% Dextran or NS (250ml each)⁴². Once again they observed improvement in SBP as well as increased survival in the HTS group. The addition of dextran however, afforded no additional survival benefit over HTS alone. The same results were put forward after a multicentric trial by this group using 7.5% HTS, 7.5% HTS/6% dextran, 7.5% HTS/12% dextran and Lactated Ringer (250ml each)⁴³.

Following these encouraging results, Cooper et al conducted a double-blinded trial using HTS as a prehospital resuscitation fluid in 229 patients with TBI and hypotension⁴⁴. Patients were randomly assigned to receive a rapid infusion of either 250 ml of 7.5% saline or 250 ml of Ringer Lactate. In addition conventional IV fluids and resuscitation protocols were followed. At hospital admission mean serum sodium level was 149 mEq/l for HTS patients vs 141 mEq/l for Ringer Lactate. Although the duration of inotropic support was less in patients receiving HTS, no significant difference was found with respect to duration of CPP >70 mm Hg or neurological outcome at 6 months after injury.

It maybe premature however, to abandon prehospital research with HTS based on this study alone. It is important to remember that therapies that are effective in the hospital may not work in the prehospital setting⁴⁵. Further studies which are larger in size need to be carried out with the goal of determining if a larger or more prolonged effect on ICP and cerebral perfusion can be achieved along with improvement in neurological outcome.

Adverse effects of HTS

The primary concerns with use of HTS are osmotic demyelination syndrome (ODS), acute renal insufficiency and hematologic abnormalities including increased hemorrhage, coagulopathy and red cell lysis.

The pathophysiology of osmotic demyelination syndrome involves destruction of myelinated structures after a rapid rise in serum sodium. The deep matter in the pons is the most susceptible. Studies on animal models have recommended avoidance of a rate of change in serum sodium greater than 10- 20 mEq/l/day^{46,47}. Human trials using HTS for ICP control generally avoid rapid rises in serum sodium and ODS has not been reported^{26,37}. Khanna et al²⁶ reported 10 patients with TBI in whom a peak serum sodium value of 171 mEq/l was attained. In 4 patients in whom MRI was done, no evidence of ODS was seen. With

bolus doses of HTS, elevated serum sodium values have not been associated with ODS. Thus it appears that HTS is safe with regard to ODS when very rapid rises in serum sodium are prevented.

Renal insufficiency is a major concern with the use of mannitol and has been reported with HTS as well. Huang et al observed a fourfold increase in renal failure with the use of HTS vs Ringer lactate in patients with TBI⁴⁸. Khanna et al²⁶ also reported temporary renal insufficiency in 2 out of 10 patients receiving HTS. However, both these patients were in sepsis and the renal failure may not have been osmotically induced. In animal models, renal insufficiency has not been observed when upto 5 times the therapeutic human doses were used⁴⁹. Further studies with varying dosage regimes will better define this risk with the use of HTS.

Bleeding complications following rapid fluid resuscitation have been described with both HTS and isotonic fluids^{50,51}. This concern exists primarily when active hemorrhage cannot be controlled due to unavailable resources. This may not be valid in a setting of TBI where hypotension is not well tolerated and maybe detrimental to neurological outcome.

A rebound rise in ICP has been described with use of HTS for ICP control, both when given as a bolus or after cessation of continuous infusion²⁶. However, it is still unclear whether this rise in ICP is truly a "rebound" effect or simply a reflection of the limited half-life of the osmotic agent.

CONCLUSION

The ability of HTS to treat raised ICP appears to occur through a variety of mechanisms including optimization of systemic and cerebral hemodynamics, reduction of cerebral edema and modulation of cerebral immunology and neurochemistry. The adverse effects of HTS are common to all osmotic agents including concern for ODS, renal insufficiency and rebound ICH. The relative safety and efficacy of HTS vs. mannitol has yet to be proven in human trials although animal studies seem to be favorably inclined towards HTS. The use of HTS for resuscitation in trauma patients is less well defined and there is still paucity of well controlled studies in prehospital trials. The ability of HTS to restore blood pressure without increasing cerebral edema and ICP is more definite. What remains less clear is whether HTS really offers a significant advantage over isotonic fluids in general trauma. In the case of TBI, HTS salvage therapy has been resorted to mostly when other measures like mannitol and barbiturates have failed to decrease ICP. Further human studies need

to be carried out to ascertain whether HTS really has a significant advantage when compared to mannitol in human subjects with TBI. In addition, the optimal regimens for HTS, whether bolus or continuous infusion as well as the ideal concentration to be used need to be addressed.

REFERENCES

1. Shackford SR, Mackenzie RC, Holbrook TI et al. The epidemiology of traumatic death: A population based analysis. *Arch Surg* 1993; 128: 571-5.
2. Chestnut RM, Marshall LS, Klauber M et al. The role of secondary brain injury in determining outcome from severe head injury. *J Trauma* 1993; 34: 216-22.
3. Marshall LF, Smith RW, Shapiro HM. The outcome with aggressive treatment in severe head injuries. Part I. The significance of intracranial pressure monitoring. *J Neurosurg* 1979; 50: 20-5.
4. Chestnut RM. Medical management of severe head injury: Present and future. *New Horiz* 1995; 3: 551-93.
5. Arai T, Tsukahara I, Nitta K et al. Effects of mannitol on cerebral circulation after transient complete cerebral ischaemia in dogs. *Crit Care Med* 1986; 14: 634-7.
6. Shackford SR, Bourguignon RR, Wald SL et al. Hypertonic saline resuscitation of patients with head injury. A prospective randomized clinical trial. *J Trauma* 1998; 44: 50-8.
7. Weed LH, McKibben PS. Pressure changes in cerebrospinal fluid following IV injection of solutions of various concentrations. *Am J Physiol* 1919; 48: 512-30.
8. Todd MM, Tommasino C, Moore S. Cerebral effects of isovolemic hemodilution with hypertonic saline solution. *J Neurosurg* 1986; 64: 627-34.
9. Shackford SR. Fluid resuscitation in head injury. *J Intensive Care Med* 1990; 5: 59-68.
10. Holcroft JW, Vassar MJ, Turner JE et al. 3% NaCl and 7.5% NaCl dextran for resuscitation of severely injured patients. *Ann Surg* 1987; 206: 278-88.
11. Vassar MJ, Perry CA, Gannaway WL et al. 7.5% NaCl dextran for resuscitation of trauma patients undergoing helicopter transport. *Arch Surg* 1991; 126: 1065-72.
12. Shroder ML, Muizelaar JP, Kuta AJ. Documented reversal of global ischaemia immediately after removal of an acute subdural haematoma. *J Neurosurg* 1994; 80: 324-7.
13. Chestnut RM, Gautille T, Blunt BA et al. Neurogenic hypotension in patients with severe head injuries. *J Trauma* 1998; 44: 958-64.
14. Cudd TA, Purniton S, Patel NC et al. Cardiovascular adrenocorticotropin and cortisol responses to hypertonic saline in euvoletic sheep are altered by prostaglandin synthetase inhibition. *Shock* 1998; 10: 32-36.
15. Pascnal JM, Watson JC, Runyon AE et al. Resuscitation of intraoperative hypovolemia: a comparison of normal saline and hyperosmotic / hyperoncotic solutions in swine. *Crit Care Med* 1992; 20: 200-10.

16. Qureshi A, Suarez J, Bhardwaj A et al. Use of hypertonic saline / acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. *Crit Care Med* 1998; 26: 440-6.
17. Favre J, Ravussin P, Chiolero R et al. Hypertonic solutions and intracranial pressure. *Schweiz Med Wochenachr J Suisse Med* 1996; 126: 1635-43.
18. Qureshi A, Wilson D, Traystman R. Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage : comparison between mannitol and hypertonic saline. *Neurosurgery* 1999; 44: 1055-63.
19. Videen JS, Michaclis T, Pinto T et al. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. *J Clin Invest* 1995; 95: 788-93.
20. Trachtman H. Cell volume regulation: a review of cerebral adaptive mechanisms and implications for clinical treatment of osmolal disturbances II. *Pediatr Nephrol* 1992;5: 743-50.
21. Olson JE, Banks M, Dimlich RV et al. Blood brain barrier water permeability and brain osmolyte content during edema development. *Acad Emer Med* 1997; 4: 662-73.
22. Yashamita T, Kohmura E, Yamauchi A et al. Induction of Na⁺/myositol cotransporter mRNA after focal cerebral ischaemia: evidence for extensive osmotic stress in remote areas. *J Cereb Blood Flow Metab* 1996; 16: 1203-10.
23. Yashamita T, Shimada S, Yamauchi A et al. Induction of Na⁺Myoinositol cotransporter mRNA after rat cryogenic injury. *Brain Res Mol Brain Res* 1997; 46: 236-42.
24. Pascaul JM, Watson JC, Runyon AE et al. Resuscitation of intraoperative hypovolemia a comparison of normal saline and hyperosmotic/ hyperoncotic solutions in swine. *Crit Care Med* 1992;20: 200-10.
25. Nose H, Doi Y, Usi S, Kubota T et al. Continuous measurement of sodium concentration in CSF during gastric water infusion in dehydrated rats. *J Appl Physiol* 1992; &3: 1419-24.
26. Khanna S, Davis D, Fisher B et al. Prolonged hypernatremia controls elevated intracranial pressure in pediatric head injury patients. *Crit Care Med* 2000; 26: 421-2.
27. Schroder ML, Muizelaar JP, Fatouros PP et al. Regional cerebral blood volume after severe head injury in patients with regional cerebral ischaemia. *Neurosurgery* 1998; 42: 1276-81.
28. Boldt J, Zickmann B, Herold C et al. Influence of hypertonic volume replacement on the microcirculation in cardiac surgery. *Br J Anaesth* 1991; 67: 595-602.
29. Hariri RJ, Ghajar JB, Pomerantz KB et al. Human glial cell production of lipooxygenase generated eicosanoids: a potential role in the pathophysiology of vascular changes following traumatic brain injury. *J Trauma* 1989; 29: 1203-10.
30. Cudd TA, Purinton S, Patel NC. Cardiovascular adrenocorticotropin and cortisol responses to hypertonic saline in euvolemic sheep are altered by prostaglandin synthetase inhibition. *Shock* 1998; 10: 32-6.
31. Bauer M, Marzi I, Ziegenfuss T et al. Comparative effects of crystalloid and small volume hypertonic hyperoncotic fluid resuscitation on hepatic microcirculation after hemorrhagic shock. *Circ Shock* 1993; 40: 187-93.
32. Brown JL, Baker AJ, Konasieuriez SJ et al. Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans. *J Neurotrauma* 1998; 15: 253-63.
33. Worthley LI, Cooper DJ, Jones N. Treatment of resistant intracranial hypertension with hypertonic saline solution. *J Neurosurg* 1986; 64: 627-34.
34. Einhaus S, Croce M, Watridge c et al. The use of hypertonic saline for treatment of increased intracranial pressure. *J Tenn Med Assoc* 1996; 89: 81-2.
35. Suarez J, Qureshi A, Bhardwaj A et al. Treatment of refractory intracranial hypertension with 23.4% saline. *Crit Care Med* 1998; 26: 1118-22.
36. Horn P, Meunch E, Vajkocry P et al. Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. *Neurol Res* 1999; 21: 758-64.
37. Simma B, Burger R, Falk M et al. A prospective randomized and controlled study of fluid management in children with severe head injury: Lactated ringer solution vs. hypertonic saline. *Crit Care Med* 1998; 26: 1265-70.
38. Qureshi AL, Suarez JL, Castro et al. Use of hypertonic saline/acetate infusion in treatment of cerebral edema in patients with head trauma. *J Trauma* 1999; 47: 659-65.
39. Peterson B, Khanna S, Fischer B et al. Prolonged hypernatremia controls elevated intracranial pressure in head injured pediatric patients. *Crit Care Med* 2000;28: 1136-43.
40. Fulton R, Flynn W, Mancino M et al. Brain injury causes loss of cardiovascular response to hemorrhagic shock. *J Invest Surg* 1993; 6: 117-31.
41. Anderson J, Wisner D, Sullivan P et al. Initial small volume hypertonic resuscitation of shock and brain injury: short and long term effects. *J Trauma* 1997; 42: 592-600.
42. Vassar M, Perry C, Holcroft J. Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl vs. 7.5% NaCl with added dextran :a controlled trial. *J Trauma* 1993; 34: 622-32.
43. Vassar MJ, Fischer RP, O Brian PE et al. A multicentric trial for resuscitation of injured patients with 7.5% sodium chloride .The effect of added dextran 70. *Arch Surg* 1993; 128: 1003-13.
44. Cooper DJ, Myles PS, McDermott FT et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury. *JAMA* 2004;291, 1350-7.
45. Lewis RJ. Prehospital care of the multiply injured patient. *JAMA* 2004; 291, 1382-3.
46. Sterns RH, Riggs JE, Schochet SS. Osmotic demyelination syndrome following correction of hyponatremia.

N Engl J Med 1986;317: 1535-42.

47. Laurens R, Karp BI. Myelinolysis after correction of hyponatremia. *Ann Intern Med* 1997;126:57-62
48. Huang PP, Stucky FS, Dimick AR et al. Hypertonic sodium resuscitation is associated with renal failure and death. *Ann Surg* 1995; 221: 543-57.
49. Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/ 6% dextran 70 in experimental animals and in humans.

J Trauma 1994; 36: 323-30.

50. Riddez L, Hahn RG, Suneson A et al. Central and regional hemodynamics during uncontrolled bleeding using hypertonic saline dextran for resuscitation. *Shock* 1998; 10: 176-81.
51. Krausz MM. Controversies in shock research: hypertonic resuscitation –pros and cons. *Shock* 1995; 3: 69-72.